Financials Median Technologies

Equities

Market Closed - Euronext Paris Other stock markets 11:35:15 2024-06-11 am EDT			5-day change	1st Jan Change
2.95 ^EUR	-3.28%		-13.87%	-37.89%

May. 21	Median Technologies Becomes Preferred Vendor to Another Top 3 Pharmaceutical Company	CI
Apr. 29	Median Technologies SA Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Capitalization ¹	23.85	83.53	241.4	140.2	87.31	56.1	-	-
Enterprise Value (EV) ¹	23.85	82.79	218.9	136.9	87.31	75.35	95.34	104.4
P/E ratio	-2.98 x	-6.57 x	-12.5 x	-6.95 x	-3.8 x	-2.36 x	-2.81 x	-4.01 x
Yield	-	-	-	-	-	-	-	-
Capitalization / Revenue	-	6.19 x	11.8 x	5.89 x	3.93 x	2.35 x	1.27 x	1.54 x
EV / Revenue	-	6.13 x	10.7 x	5.75 x	3.93 x	3.15 x	2.16 x	2.86 x
EV / EBITDA	-	-10.3 x	-20.1 x	-6.08 x	-4.03 x	-3.23 x	-5 x	-7.27 x
EV / FCF	-	-14.4 x	-20.6 x	-7.97 x	-4.06 x	-3.48 x	-5.18 x	-6.27 x
FCF Yield	-	-6.95%	-4.84%	-12.5%	-24.6%	-28.7%	-19.3%	-16%
Price to Book	-	-	-	-	-	-1.67 x	-0.9 x	-0.82 x
Nbr of stocks (in thousands)	12,106	12,106	15,437	15,775	18,382	18,395	-	-
Reference price ²	1.970	6.900	15.64	8.890	4.750	3.050	3.050	3.050
Announcement Date	4/14/20	4/8/21	4/21/22	4/20/23	4/25/24	-	-	-

¹EUR in Million²EUR

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	-	13.5	20.5	23.8	22.23	23.9	44.18	36.5
EBITDA ¹	-	-8.012	-10.88	-22.51	-21.66	-23.3	-19.08	-14.35
EBIT ¹	-	-8.819	-11.57	-23.36	-23.12	-23.8	-20.48	-15.3
Operating Margin	-	-65.33%	-56.43%	-98.13%	-104%	-99.58%	-46.35%	-41.92%
Earnings before Tax (EBT) ¹	-	-	-	-	-22.98	-29.05	-22.25	-
Net income ¹	-7.984	-12.8	-19.29	-20.21	-22.98	-24.93	-20.82	-16.8
Net margin	-	-94.83%	-94.11%	-84.93%	-103.4%	-104.32%	-47.14%	-46.03%
EPS ²	-0.6600	-1.050	-1.250	-1.280	-1.250	-1.290	-1.087	-0.7600
Free Cash Flow ¹	-	-5.752	-10.61	-17.18	-21.49	-21.65	-18.4	-16.65
FCF margin	-	-42.61%	-51.74%	-72.18%	-96.68%	-90.59%	-41.65%	-45.62%
FCF Conversion (EBITDA)	-	-	-	-	-	-	-	-
FCF Conversion (Net income)	-	-	-	-	-	-	-	-
Dividend per Share	-	-	-	-	-	-	-	-
Announcement Date	4/14/20	4/8/21	4/21/22	4/20/23	4/25/24	-	-	-

¹EUR in Million²EUR

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net Debt ¹	-	-	-	-	-	19.3	39.2	48.3
Net Cash position ¹	-	0.74	22.5	3.32	-	-	-	-
Leverage (Debt/EBITDA)	-	-	-	-	-	-0.8262 x	-2.057 x	-3.362 x
Free Cash Flow ¹	-	-5.75	-10.6	-17.2	-21.5	-21.7	-18.4	-16.7
ROE (net income / shareholders' equity)	-	-	-	-	-	-	-	-
ROA (Net income/ Total Assets)	-	-	-	-	-	-	-	-
Assets ¹	-	-	-	-	-	-	-	-
Book Value Per Share ²	-	-	-	-	-	-1.830	-3.410	-3.710
Cash Flow per Share ²	-	-0.4500	-0.6500	-1.000	-1.100	-1.280	-1.060	-
Capex ¹	-	-	-	1.39	1.25	1.3	1.75	1.3
Capex / Sales	-	-	-	5.83%	5.64%	5.44%	3.96%	3.56%
Announcement Date	4/14/20	4/8/21	4/21/22	4/20/23	4/25/24	-	-	-

¹EUR in Million²EUR

Estimates

Trading Rating

Investor Rating

ESG Refinitiv

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.05 EUR

Average target price

24.18 EUR

Spread / Average Target

+692.62%

	1st Jan change	Capi.
MEDIAN TECHNOLOGIES	-37.89%	60.28M
THERMO FISHER SCIENTIFIC	+8.60%	222B
INTUITIVE SURGICAL, INC.	+24.30%	148B
BOSTON SCIENTIFIC CORPORATION	+33.09%	114B
SIEMENS HEALTHINEERS AG	+4.45%	65.69B
EDWARDS LIFESCIENCES CORPORATION	+14.65%	51.88B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+4.08%	50.02B
AGILENT TECHNOLOGIES, INC.	-4.61%	38.81B
GE HEALTHCARE TECHNOLOGIES INC.	-3.01%	34.59B
RESMED, INC.	+23.10%	31.09B